Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 9/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31228792 | 1.00 | PIM1 (0.41) | PIM1DGAT1PTPN1GRM2KMT2A | |
| SCHEMBL30601029 | 0.82 | KDM4E (0.46) | KMT2ALMNA | |
| SCHEMBL319252 | 0.82 | KDM4E (0.46) | KMT2ALMNA | |
| SCHEMBL13362749 | 0.78 | PIM1 (0.50) | PIM1PTPN1GRM2KMT2ALMNA | |
| SCHEMBL16751982 | 0.76 | APP (0.42) | PIM1DGAT1PTPN1GRM2KMT2A | |
| SCHEMBL31507586 | 0.76 | PIM1 (0.41) | PIM1DGAT1PTPN1GRM2KMT2A | |
| SCHEMBL29502454 | 0.76 | TGFBR1 (0.42) | PIM1GRM2KMT2ALMNAAPP | |
| SCHEMBL26684509 | 0.76 | PIM1 (0.41) | PIM1DGAT1PTPN1GRM2KMT2A | |
| SCHEMBL2827339 | 0.76 | TGFBR1 (0.42) | PIM1GRM2KMT2ALMNAAPP | |
| SCHEMBL11347729 | 0.76 | KMT2A (0.39) | PIM1PTPN1GRM2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454529-B2 | Piperazine cyclic ureas | Sironax Ltd. (KY) | 2025-10-28 | — | — | US | disclosed |
| CN-115697991-B | Piperazine cyclic ureas | 维泰瑞隆有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024067845-A1 | IMIDAZOPYRIDINE COMPOUND AS IRAK4 DEGRADATION AGENT AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2024-04-04 | — | — | WO | disclosed |
| CN-117777126-A | Imidazopyridines as IRAK4 degradants and uses thereof | 武汉人福创新药物研发中心有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-4153582-A1 | PIPERAZINE CYCLIC UREAS | Sironax Ltd. (KY) | 2023-03-29 | — | — | EP | disclosed |
| CN-115697991-A | Piperazine cyclic ureas | 维泰瑞隆有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021233397-A1 | PIPERAZINE CYCLIC UREAS | Sironax Ltd. (KY) | 2021-11-25 | — | — | WO | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160185797-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| EP-3036229-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| WO-2015025026-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | PIM1 3403/4885DGAT1 677/4885PTPN1 2945/4885 |
| US-12454529-B2 | Piperazine cyclic ureas | RIPK1, RIPK3, RIPK4 | PIM1 815/4885DGAT1 3635/4885PTPN1 1653/4885 |
| US-20160185797-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | PIM1 3403/4885DGAT1 677/4885PTPN1 2945/4885 |
| US-20160176850-A1 | AXL INHIBITORS | AXL, FLT3, MERTK | PIM1 88/4885DGAT1 4204/4885PTPN1 210/4885 |
| US-20230203019-A1 | Piperazine Cyclic Ureas | RIPK1, RIPK3, RIPK4 | PIM1 815/4885DGAT1 3635/4885PTPN1 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.